Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future

Seminars in Immunology

Volumn 28, Issue 3, 2016, Pages 223-240

  Risitano, Antonio M ^a   Marotta, Serena ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

aHUS; C3; C5; CAD; Complement therapeutics; Compstatin; Eculizumab; PNH

Indexed keywords

ANTIANEMIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C5 INHIBITOR; COMPSTATIN; COVERSIN; CYCLOMIMETICS; ECULIZUMAB; ENZYME INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; COMPLEMENT; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

AUTOIMMUNE HEMOLYTIC ANEMIA; COLD AGGLUTININE DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; HEMOGLOBINURIA; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; LONG TERM CARE; PAROXYSMAL COLD HEMOGLOBINURIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PERSONALIZED MEDICINE; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOTHERAPY; PRECISION MEDICINE; THROMBOTIC MICROANGIOPATHIES;

EID: 84991765484     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.05.001     Document Type: Review

References (201)

1. [1] Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11 (2010), 785–797.
2. [2] Varela, J.C., Tomlinson, S., Complement an overview for the clinician. Hematol. Oncol. Clin. North Am. 29:June (3) (2015), 409–427, 10.1016/j.hoc.2015.02.001.
3. [3] Ricklin, D., Lambris, J.D., Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190 (2013), 3831–3838.
4. [4] Holers, V.M., The spectrum of complement alternative pathway-mediated diseases. Immunol. Rev. 223 (2008), 300–316.
5. [5] Rother, R.P., Rollins, S.A., Mojcik, C.F., et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25 (2007), 1256–1264.
6. [6] Risitano, A.M., Paroxysmal nocturnal hemoglobinuria. Silverberg, D., (eds.) Anemia, 2012, InTech (2012).
7. [7] Luzzatto, L., Notaro, R., Paroxysmal nocturnal hemoglobinuria. Handin, R.I., Lux, S.E., Stossel, T.P., (eds.) Blood, Principles and Practice of Hematology, 2nd ed., 2003, Lippincot Williams & Wilkins, Philadelphia, PA (USA), 319–334.
8. [8] Parker, C.J., Ware, R.E., et al. Paroxysmal nocturnal hemoglobinuria. Greer, J., (eds.) Wintrobe's Clinical Hematology, 11th ed., 2003, Lippincot Williams & Wilkins, Philadelphia, 1203–1221.
9. [9] Miyata, T., Takeda, J., Iida, Y., et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 259 (1993), 1318–1320.
10. [10] Takeda, J., Miyata, T., Kawagoe, K., et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 (1993), 703–711.
11. [11] Nicholson-Weller, A., Burge, J., Fearon, D.T., Weller, P.F., Austen, K.F., Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129:1 (1982), 184–189.
12. [12] Nicholson-Weller, A., Decay accelerating factor (CD55). Curr. Top. Microbiol. Immunol. 178 (1992), 7–30.
13. [13] Holguin, M.H., Fredrick, L.R., Bernshaw, N.J., et al. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J. Clin. Invest. 84 (1989), 7–17.
14. [14] Meri, S., Morgan, B.P., Davies, A., Daniels, R.H., Olavesen, M.G., Waldmann, H., Lachmann, P.J., Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1 (1990), 1–9.
15. [15] Hillmen, P., Young, N.S., Schubert, J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355 (2006), 1233–1243.
16. [16] Brodsky, R.A., Young, N.S., Antonioli, E., et al. Multicenter phase III study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 114 (2008), 1840–1847.
17. [17] Hillmen, P., Muus, P., Duhrsen, U., et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110 (2007), 4123–4128.
18. [18] Rother, R.P., Bell, L., Hillmen, P., et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293 (2005), 1653–1662.
19. [19] Helley, D., de Latour, R.P., Porcher, R., French Society of Hematology, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 95 (2010), 574–581.
20. [20] Weitz, I.C., Razavi, P., Rochanda, L., Zwicker, J., Furie, B., Manly, D., Mackman, N., Green, R., Liebman, H.A., Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb. Res. 130:September (3) (2012), 361–368.
21. [21] Kelly, R.J., Hill, A., Arnold, L.M., et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117 (2011), 6786–6792.
22. [22] Hillmen, P., Lewis, S.M., Bessler, M., et al. Natural history of paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 333 (1995), 1253–1258.
23. [23] Socie, G., Mary, J.Y., de Gramont, A., et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 348 (1996), 573–577.
24. [24] de Latour, R.P., Mary, J.Y., Salanoubat, C., Terriou, L., Etienne, G., Mohty, M., Roth, S., de Guibert, S., Maury, S., Cahn, J.Y., Socié, G., French Society of Hematology, French Association of Young Hematologists, Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 112:October (8) (2008), 3099–3106.
25. [25] Loschi, M., Porcher, R., Barraco, F., Terriou, L., Mohty, M., de Guibert, S., Mahe, B., Lemal, R., Dumas, P.Y., Etienne, G., Jardin, F., Royer, B., Bordessoule, D., Simon Rohrlich, P., Fornecker, L.M., Salanoubat, C., Maury, S., Cahn, J.Y., Vincent, L., Sene, T., Rigaudeau, S., Nguyen, S., Lepretre, A.C., Mary, J.Y., Corront, B., Socie, G., de Latour, R.P., Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am. J. Hematol., 2015, 10.1002/ajh.24278 (Dec 21. [Epub ahead of print]).
26. [26] Noris, M., Remuzzi, G., Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361 (2009), 1676–1687.
27. [27] Loirat, C., Frémeaux-Bacchi, V., Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 6 (2011), 60–89.
28. [28] Sperati, C.J., Moliterno, A.R., Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome. Hematol. Oncol. Clin. North Am. 29:June (3) (2015), 541–559, 10.1016/j.hoc.2015.02.002.
29. [29] Kavanagh, D., Richards, A., Atkinson, J., Complement regulatory genes and haemolytic uremic syndromes. Annu. Rev. Med. 59 (2008), 293–309.
30. [30] Kavanagh, D., Goodship, T., Genetics and complement in atypical HUS. Pediatr. Nephrol. 25 (2010), 2431–2442.
31. [31] Fan, X., Yoshida, Y., Honda, S., Matsumoto, M., Sawada, Y., Hattori, M., Hisanaga, S., Hiwa, R., Nakamura, F., Tomomori, M., Miyagawa, S., Fujimaru, R., Yamada, H., Sawai, T., Ikeda, Y., Iwata, N., Uemura, O., Matsukuma, E., Aizawa, Y., Harada, H., Wada, H., Ishikawa, E., Ashida, A., Nangaku, M., Miyata, T., Fujimura, Y., Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol. Immunol. 54:June (2) (2013), 238–246.
32. [32] Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.A., Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., Burtey, S., Niaudet, P., Deschênes, G., Lebranchu, Y., Zuber, J., Loirat, C., Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8:April (4) (2013), 554–562.
33. [33] Legendre, C.M., Licht, C., Muus, P., Greenbaum, L.A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D.J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R.R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nürnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N.S., Trivelli, A., Zimmerhackl, L.B., Goodship, T., Loirat, C., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368:June (23) (2013), 2169–2181.
34. [34] Cataland, S.R., Wu, H.M., How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 123:April (16) (2014), 2478–2484.
35. [35] Zuber, J., Fakhouri, F., Roumenina, L.T., Loirat, C., Frémeaux-Bacchi, V., French Study Grou for aHUS/C3G, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat. Rev. Nephrol. 8:November (11) (2012), 643–657.
36. [36] Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., Karpman, D., Landau, D., Langman, C.B., Lapeyraque, A.L., Licht, C., Nester, C., Pecoraro, C., Riedl, M., van de Kar, N.C., Van de Walle, J., Vivarelli, M., Frémeaux-Bacchi, V., HUS International, An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. 31:January (1) (2016), 15–39, 10.1007/s00467-015-3076-8.
37. [37] Risitano, A.M., Notaro, R., Marando, L., et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113 (2009), 4094–4100.
38. [38] Hill, A., Rother, R.P., Arnold, L., et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 95 (2010), 567–573.
39. [39] Nishimura, J., Yamamoto, M., Hayashi, S., et al. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 370:7 (2014), 632–639.
40. [40] Hillmen, P., Muus, P., Roth, A., et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br. J. Haematol. 162:1 (2013), 62–73.
41. [41] Marotta, S., Giagnuolo, G., Basile, S., Pagliuca, S., Grimaldi, F., Pane, F., Risitano, A.M., Excellent outcome of concomitant intensive immunosuppression and eculizumab in aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome. J. Hematol. Thromb. Dis., 2(1), 2014, 128.
42. [42] Lin, Z., Schmidt, C.Q., Koutsogiannaki, S., Ricci, P., Risitano, A.M., Lambris, J.D., Ricklin, D., Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood 126:August (7) (2015), 891–894, 10.1182/blood-2015-02-625871.
43. [43] Luzzatto, L., Risitano, A.M., Notaro, R., Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica 95:4 (2010), 523–526.
44. [44] Risitano, A.M., Marando, L., Seneca, E., Rotoli, B., Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood 112:2 (2008), 449–451.
45. [45] Risitano, A.M., Notaro, R., Luzzatto, L., Hill, A., Kelly, R., Hillmen, P., Paroxysmal nocturnal hemoglobinuria–hemolysis before and after eculizumab. N. Engl. J. Med. 363:23 (2010), 2270–2272.
46. [46] Rondelli, T., Risitano, A.M., Peffault de Latour, L.R., et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica 99:2 (2014), 262–266.
47. [47] Risitano, A.M., Notaro, R., Luzzatto, L., et al. Paroxysmal nocturnal hemoglobinuria: hemolysis before and after eculizumab. New Engl. J. Med. 363 (2010), 2270–2272.
48. [48] Risitano, A.M., Marando, L., Seneca, E., et al. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood 112 (2008), 449–451.
49. [49] Brodsky, R.A., How I treat paroxysmal nocturnal hemoglobinuria. Blood 113 (2009), 6522–6527.
50. [50] Keir, L.S., Shiga toxin associated hemolytic uremic syndrome. Hematol. Oncol. Clin. North Am. 29:June (3) (2015), 525–539, 10.1016/j.hoc.2015.01.007.
51. [51] Morigi, M., Galbusera, M., Gastoldi, S., Locatelli, M., Buelli, S., Pezzotta, A., Pagani, C., Noris, M., Gobbi, M., Stravalaci, M., Rottoli, D., Tedesco, F., Remuzzi, G., Zoja, C., Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J. Immunol. 187:July (1) (2011), 172–180, 10.4049/jimmunol.1100491.
52. [52] Zoja, C., Buelli, S., Morigi, M., Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr. Nephrol. 25:November (11) (2010), 2231–2240, 10.1007/s00467-010-1522-1.
53. [53] Thurman, J.M., Marians, R., Emlen, W., Wood, S., Smith, C., Akana, H., Holers, V.M., Lesser, M., Kline, M., Hoffman, C., Christen, E., Trachtman, H., Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4:December (12) (2009), 1920–1924, 10.2215/CJN.02730409 (Epub 2009 Oct 9).
54. [54] Michael, M., Elliott, E.J., Craig, J.C., Ridley, G., Hodson, E.M., Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am. J. Kidney Dis. 53:February (2) (2009), 259–272, 10.1053/j.ajkd.2008.07.038.
55. [55] Lapeyraque, A.L., Malina, M., Fremeaux-Bacchi, V., Boppel, T., Kirschfink, M., Oualha, M., Proulx, F., Clermont, M.J., Le Deist, F., Niaudet, P., Schaefer, F., Eculizumab in severe Shiga-toxin-associated HUS. N. Engl. J. Med. 364:June (26) (2011), 2561–2563, 10.1056/NEJMc1100859.
56. [56] Kielstein, J.T., Beutel, G., Fleig, S., Steinhoff, J., Meyer, T.N., Hafer, C., Kuhlmann, U., Bramstedt, J., Panzer, U., Vischedyk, M., Busch, V., Ries, W., Mitzner, S., Mees, S., Stracke, S., Nürnberger, J., Gerke, P., Wiesner, M., Sucke, B., Abu-Tair, M., Kribben, A., Klause, N., Schindler, R., Merkel, F., Schnatter, S., Dorresteijn, E.M., Samuelsson, O., Brunkhorst, R., Collaborators of the DGfN STEC-HUS registry, Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol. Dial. Transplant. 27:October (10) (2012), 3807–3815, 10.1093/ndt/gfs394.
57. [57] Delmas, Y., Vendrely, B., Clouzeau, B., Bachir, H., Bui, H.N., Lacraz, A., Hélou, S., Bordes, C., Reffet, A., Llanas, B., Skopinski, S., Rolland, P., Gruson, D., Combe, C., Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol. Dial. Transplant. 29:March (3) (2014), 565–572, 10.1093/ndt/gft470.
58. [58] Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M., Lämmle, B., von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med. 339:November (22) (1998), 1578–1584.
59. [59] Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, J.D. Jr., Ginsburg, D., Tsai, H.M., Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:October (6855) (2001), 488–494.
60. [60] Tsai, H.M., Lian, E.C., Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 339:November (22 (1998), 1585–1594.
61. [61] Zheng, X., Chung, D., Takayama, T.K., Majerus, E.M., Sadler, J.E., Fujikawa, K., Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 276:November (44) (2001), 41059–41063 (Epub 2001 Sep 13).
62. [62] Dong, J.F., Moake, J.L., Nolasco, L., Bernardo, A., Arceneaux, W., Shrimpton, C.N., Schade, A.J., McIntire, L.V., Fujikawa, K., López, J.A., ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100:December (12) (2002), 4033–4039 (Epub 2002 Jul 25).
63. [63] Turner, N., Sartain, S., Moake, J., Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes. Hematol. Oncol. Clin. North Am. 29:June (3) (2015), 509–524.
64. [64] Tati, R., Kristoffersson, A.C., Ståhl, A.L., Rebetz, J., Wang, L., Licht, C., Motto, D., Karpman, D., Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J. Immunol. 191:September (5) (2013), 2184–2193, 10.4049/jimmunol.1301221.
65. [65] Cataland, S.R., Holers, V.M., Geyer, S., Yang, S., Wu, H.M., Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 123:June (24) (2014), 3733–3788, 10.1182/blood-2013-12-547067.
66. [66] Turner, N., Nolasco, L., Nolasco, J., Sartain, S., Moake, J., Thrombotic microangiopathies and the linkage between von Willebrand factor and the alternative complement pathway. Semin. Thromb. Hemost. 40:July (5) (2014), 544–550, 10.1055/s-0034-1383547.
67. [67] Feng, S., Liang, X., Cruz, M.A., Vu, H., Zhou, Z., Pemmaraju, N., Dong, J.F., Kroll, M.H., Afshar-Kharghan, V., The interaction between factor H and Von Willebrand factor. PLoS One, 8(August (8)), 2013, e73715, 10.1371/journal.pone.0073715.
68. [68] Hu, X.U., Bao, J., Ueda, Y., Miwa, T., Song, W., Zheng, X.L., Complement activation may trigger the onset of thrombotic thrombocytopenic purpura in patients with severe ADAMTS13 deficiency. Blood, 124, 2014, 600 (abs).
69. [69] Tsai, E., Chapin, J., Laurence, J.C., Tsai, H.M., Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br. J. Haematol. 162:August (4) (2013), 558–559, 10.1111/bjh.12387 (Epub 2013 May 21).
70. [70] Laskin, B.L., Goebel, J., Davies, S.M., Jodele, S., Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 11:August (6) (2011), 1452–1462, 10.1182/blood-2011-02-321315.
71. [71] Ruutu, T., Barosi, G., Benjamin, R.J., Clark, R.E., George, J.N., Gratwohl, A., Holler, E., Iacobelli, M., Kentouche, K., Lämmle, B., Moake, J.L., Richardson, P., Socié, G., Zeigler, Z., Niederwieser, D., Barbui, T., European Group for Blood and Marrow Transplantation, European LeukemiaNet, Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 92:January (1) (2007), 95–100.
72. [72] Ho, V.T., Cutler, C., Carter, S., Martin, P., Adams, R., Horowitz, M., Ferrara, J., Soiffer, R., Giralt, S., Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 11:August (8) (2005), 571–575.
73. [73] Jodele, S., Hirsch, R., Laskin, B., Davies, S., Witte, D., Chima, R., Pulmonary arterial hypertension in pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Biol. Blood Marrow Transplant. 19:February (2) (2013), 202–207, 10.1016/j.bbmt.2012.08.022.
74. [74] El-Bietar, J., Warren, M., Dandoy, C., Myers, K.C., Lane, A., Wallace, G., Davies, S.M., Jodele, S., Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 21:November (11) (2015), 1994–2001, 10.1016/j.bbmt.2015.06.016.
75. [75] Jodele, S., Laskin, B.L., Dandoy, C.E., Myers, K.C., El-Bietar, J., Davies, S.M., Goebel, J., Dixon, B.P., A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 29:May (3) (2015), 191–204, 10.1016/j.blre.2014.11.001.
76. [76] Jodele, S., Davies, S.M., Lane, A., Khoury, J., Dandoy, C., Goebel, J., Myers, K., Grimley, M., Bleesing, J., El-Bietar, J., Wallace, G., Chima, R.S., Paff, Z., Laskin, B.L., Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124:July (4) (2014), 645–653, 10.1182/blood-2014-03-564997.
77. [77] Jodele, S., Licht, C., Goebel, J., Dixon, B.P., Zhang, K., Sivakumaran, T.A., Davies, S.M., Pluthero, F.G., Lu, L., Laskin, B.L., Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 122:September (12) (2013), 2003–2007, 10.1182/blood-2013-05-501445.
78. [78] Jodele, S., Zhang, K., Zou, F., Laskin, B., Dandoy, C.E., Myers, K.C., Lane, A., Meller, J., Medvedovic, M., Chen, J., Davies, S.M., The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 127:February (8) (2016), 989–996, 10.1182/blood-2015-08-663435.
79. [79] Ricklin, D., Cines, D.B., TMA. beware of complements. Blood 122:September (12) (2013), 1997–1999, 10.1182/blood-2013-07-512707.
80. [80] de Latour, R. Peffault, Xhaard, A., Fremeaux-Bacchi, V., Coppo, P., Fischer, A.M., Helley, D., Socié, S., Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br. J. Haematol. 161:April (2) (2013), 279–280, 10.1111/bjh.12202.
81. [81] de Fontbrune, F.S., Galambrun, C., Sirvent, A., Huynh, A., Faguer, S., Nguyen, S., Bay, J.O., Neven, B., Moussi, J., Simon, L., Xhaard, A., Resche-Riggon, M., O'Meara, A., Fremeaux-Bacchi, V., Veyradier, A., Coppo, G., de Latour, R.P., Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99:September (9) (2015), 1953–1959, 10.1097/TP.0000000000000601.
82. [82] Jodele, S., Fukuda, T., Vinks, A., Mizuno, K., Laskin, B.L., Goebel, J., Dixon, B.P., Teusink, A., Pluthero, F.G., Lu, L., Licht, C., Davies, S.M., Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol. Blood Marrow Transplant. 20:April (4) (2014), 518–525, 10.1016/j.bbmt.2013.12.565.
83. [83] Jodele, S., Fukuda, T., Mizuno, K., Vinks, A.A., Laskin, B.L., Goebel, J., Dixon, B.P., Chima, R.S., Hirsch, R., Teusink, A., Lazear, D., Lane, A., Myers, K.C., Dandoy, C.E., Davies, S.M., Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 22:February (2) (2016), 307–315, 10.1016/j.bbmt.2015.10.002.
84. [84] Berentsen, S., Randen, U., Tjønnfjord, G.E., Cold agglutinin-mediated autoimmune hemolytic anemia. Hematol. Oncol. Clin. North Am. 29:June (3) (2015), 455–471, 10.1016/j.hoc.2015.01.002.
85. [85] Schreiber, A.D., Frank, M.M., Role of antibody and complement in the immune clearance and destruction of erythrocytes: I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 51:March (3) (1972), 575–582.
86. [86] Berentsen, S., How I manage cold agglutinin disease. Br. J. Haematol. 153:May (3) (2011), 309–317.
87. [87] Swiecicki, P.L., Hegerova, L.T., Gertz, M.A., Cold agglutinin disease. Blood 122:August (7) (2013), 1114–1121.
88. [88] Roth, A., Huttmann, A., Rother, R.P., Duhrsen, U., Philipp, T., Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 113 (2009), 3885–3886.
89. [89] Roth, A., Duhrsen, U., Cold agglutinin disease. Eur. J. Haematol., 84, 2010, 91.
90. [90] Röth, A., Bommer, M., Hüttmann, A., Herich-Terhürne, D., Kuklik, N., Veronika, L., Schrezenmeier, H., Dührsen, U., Complement inhibition with eculizumab in patients with cold agglutinin disease (CAD): results from a prospective phase II trial (DECADE trial). Blood, 126, 2015, 274 (abs).
91. [91] Shanbhag, S., Spivak, J., Paroxysmal cold hemoglobinuria. Hematol. Oncol. Clin. North Am. 29:June (3) (2015), 473–478, 10.1016/j.hoc.2015.01.004.
92. [92] Parker, C.J., et al. Mechanisms of immune destruction of erythrocytes. Greer, J., (eds.) Wintrobe's Clinical Hematology, 11th ed., 2003, Lippincott Williams & Wilkins, Philadelphia, 1139–1155.
93. [93] Gregory, G.P., Opat, S., Quach, H., Shortt, J., Tran, H., Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Ann. Hematol. 90:August (8) (2011), 989–990, 10.1007/s00277-010-1123-x.
94. [94] Zanella, A., Barcellini, W., Treatment of autoimmune hemolytic anemias. Haematologica 99:October (10) (2014), 1547–1554, 10.3324/haematol.2014.114561.
95. [95] Bommer, M., Höchsmann, B., Flegel, W., Döhner, H., Schrezenmeier, H., Successful treatment of complement mediated refractory hemolysis associated with cold and warm autoantibodies using eculizumab. Haematologica, 94(Suppl. 2), 2011, 241 (abs. 0593).
96. [96] Wouters, D., Stephan, F., Strengers, P., de Haas, M., Brouwer, C., Hagenbeek, A., van Oers, M.H., Zeerleder, S., C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood 121:February (7) (2013), 1242–1244, 10.1182/blood-2012-11-467209.
97. [97] Chao, M.P., Hong, J., Kunder, C., Lester, L., Schrier, S.L., Majeti, R., Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss syndrome responsive to eculizumab and rituximab. Am. J. Hematol. 90:January (1) (2015), 78–81, 10.1002/ajh.23791.
98. [98] Ricklin, D., Lambris, J.D., Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 190 (2013), 3839–3847.
99. [99] Ricklin, D., Lambris, J.D., Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 735 (2013), 1–22.
100. [100] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02605993.
101. [101] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01624636.
102. [102] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02534909.
103. [103] Adienne Pharma & Biotech. 2014. http://www.adienne.com/en/rd/pipeline/mubodina®.html.
104. [104] Marzari, R., Sblattero, D., Macor, P., Fischetti, F., Gennaro, R., Marks, J.D., Bradbury, A., Tedesco, F., The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur. J. Immunol. 32:10 (2002), 2773–2782.
105. [105] Woodruff, T.M., Nandakumar, K.S., Tedesco, F., Inhibiting the C5-C5a receptor axis. Mol. Immunol. 48:14 (2011), 1631–1642.
106. [106] Borodovsky, A., Yucius, K.K., Sprague, A., Butler, J., Fishman, S., Nguyen, T., Vaishnaw, A., Maier, M., Kallanthottathil, R., Kuchimanchi, S., Manoharan, M., Meyers, R., Fitzgerald, K., Development of RNAi therapeutics targeting the complement pathway. Blood, 122(21), 2013, 2471.
107. [107] Borodovsky, A., Yucius, K., Sprague, A., Banda, N.K., Holers, V.M., Vaishnaw, A., Maier, M., Kallanthottathil, R., Charisse, K., Kuchimanchi, S., Manoharan, M., Salant, D.J., Fitzgerald, K., Meyers, R., Sorensen, B., Aln-CC5, an investigational RNAi therapeutic targeting C5 for complement inhibition. Blood, 124, 2014, 1606.
108. [108] Hill, A., Taubel, J., Bush, J., Borodovsky, A., Kawahata, N., Mclean, H., Powell, C., Chaturvedi, P., Warner, G., Garg, P., Sorensen, B., A subcutaneously administered investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: interim phase 1 study results. Blood, 126, 2015, 2413.
109. [109] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02352493.
110. [110] Nunn, M.A., Sharma, A., Paesen, G.C., et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J. Immunol. 174:4 (2005), 2084–2091.
111. [111] Roversi, P., Lissina, O., Johnson, S., et al. The structure of OMCI, a novel lipocalin inhibitor of the complement system. J. Mol. Biol. 369:3 (2007), 784–793.
112. [112] Barratt-Due, A., Thorgersen, E.B., Lindstad, J.K., et al. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J. Immunol. 187:9 (2011), 4913–4919.
113. [113] Weston-Davies, W.H., Westwood, J.P., Nunn, M., et al. Phase I. Clinical trial of coversin, a novel complement C5 and LTB4 inhibitor. Paper Presented at: 7th International Conference on Complement Therapeutics, Olympia, June 6–11, 2014, 2014 (Aegean Conferences 82, abs 31).
114. [114] Weston-Davies, W.H., Nunn, M.A., Pinto, F.O., Mackie, I.J., Richards, S.J., Machin, S.J., Prudo, M., Hillmen, P., Clinical and immunological characterisation of coversin, a novel small protein inhibitor of complement C5 with potential as a therapeutic agent in PNH and other complement mediated disorders. Blood, 124, 2014, 4280 (published ahead of print December 5, 2014).
115. [115] Ueda, Y., Osato, M., Weston-Davies, W., Nunn, M.A., Hayashi, S., Nishimura, J., Kanakura, Y., Coversin blocked in vitro hemolysis in an eculizumab-resistant PNH patient with the C5 polymorphism (c.2654G>A). Blood, 126, 2015, 2138.
116. [116] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02591862.
117. [117] Josephson, K., Ricardo, A., Szostak, J.W., mRNA display: from basic principles to macrocycle drug discovery. Drug Discov. Today 19:4 (2014), 388–399.
118. [118] Ricardo, A., Arata, M., DeMarco, S., Dhamnaskar, K., Hammer, R., Josephson, K., Seyb, K., Tobe, S., Wang, Z., Zheng, H., Treco, D., Development of RA101348, a potent cyclic peptide inhibitor of C5 for complement-mediated diseases. Blood, 2014(124), 2014, 2936.
119. [119] Ricardo, A., Arata, M., DeMarco, S., Dhamnaskar, K., Hammer, R., Fridkis-Hareli, M., Rajagopal, V., Seyb, K., Tang, G.Q., Tobe, S., Treco, D., Preclinical evaluation of RA101495, a potent cyclic peptide inhibitor of C5 for the treatment of paroxysmal nocturnal hemoglobinuria. Blood, 126, 2015, 939.
120. [120] Cox, J.C., Rajendran, M., Riedel, T., Davidson, E.A., Sooter, L.Y., Bayer, T.S., Schmitz-Brown, M., Ellington, A.D., Automated acquisition of aptamer sequences. Comb. Chem. High Throughput Screen. 5:4 (2002), 289–2299.
121. [121] Leung, E., Landa, G., Update on current and future novel therapies for dry age-related macular degeneration. Exp. Rev. Clin. Pharmacol. 6:5 (2013), 565–579.
122. [122] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00950638.
123. [123] Drolet, D.W., Zhang, C., O'Connell, D.J., Gupta, S., Janjic, N., SOMAmer inhibitors of the complement system. Paper Presented at: 7th International Conference on Complement Therapeutics, Olympia, June 6–11, 2014, 2014 (Aegean Conferences 82, abs 23).
124. [124] Feldwisch, J., Tolmachev, V., Engineering of affibody molecules for therapy and diagnostics. Methods Mol. Biol., 2012, 899103–899126.
125. [125] Strömberg, P., Introducing SOBI002, a small Affibody-ABD fusion protein targeting complement component C5. Paper Presented at: 7th International Conference on Complement Therapeutics, Olympia, June 6–11, 2014, 2014 (Aegean Conferences 82, abs 30).
126. [126] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT02083666.
127. [127] Pangburn, M.K., Müller-Eberhard, H.J., Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann. N. Y. Acad. Sci. 421 (1983), 291–298.
128. [128] Lindorfer, M.A., Pawluczkowycz, A.W., Peek, E.M., Hickman, K., Taylor, R.P., Parker, C.J., A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 115:11 (2010), 2283–2291.
129. [129] Paixao-Cavalcante, D., Torreira, E., Lindorfer, M.A., et al. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. J. Immunol. 192:10 (2014), 4844–4851.
130. [130] Sahu, A., Kay, B.K., Lambris, J.D., Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157:2 (1996), 884–891.
131. [131] Ricklin, D., Lambris, J.D., Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 632 (2008), 273–292.
132. [132] Mastellos, D.C., Yancopoulou, D., Kokkinos, P., Huber-Lang, M., Hajishengallis, G., Biglarnia, A.R., Lupu, F., Nilsson, B., Risitano, A.M., Ricklin, D., Lambris, J.D., Compstatin a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur. J. Clin. Invest. 45:April (4) (2015), 423–440, 10.1111/eci.12419.
133. [133] Ricklin, D., Lambris, J.D., Complement in immune and inflammatory disorders: therapeutic interventions. J. Immunol. 190:8 (2013), 3839–3847.
134. [134] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT00473928.
135. [135] Qu, H., Magotti, P., Ricklin, D., et al. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol. Immunol. 48:4 (2011), 481–489.
136. [136] Qu, H., Ricklin, D., Bai, H., et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 218:4 (2013), 496–505.
137. [137] Magotti, P., Ricklin, D., Qu, H., Wu, Y.Q., Kaznessis, Y.N., Lambris, J.D., Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J. Mol. Recognit. 22:6 (2009), 495–505.
138. [138] Risitano, A.M., Ricklin, D., Huang, Y., et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 123:13 (2014), 2094–2101.
139. [139] Kaudlay, P., Hua, H., He, G., Newton, D.J., Varghese, A.M., Munir, T., Hill, A., Kelly, R.J., Richards, S.J., Hillmen, P., Red cell complement loading in PNH patients on eculizumab is associated with a C3 polymorphism which influences C3 function, predicts for increased extravascular hemolysis and provides a rationale for C3 inhibition. Blood, 122(21), 2013, 2466.
140. [140] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT02264639.
141. [141] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT02588833.
142. [142] Bexborn, F., Andersson, P.O., Chen, H., Nilsson, B., Ekdahl, K.N., The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). Mol. Immunol. 45:April (8) (2008), 2370–2379.
143. [143] Noris, M., Mescia, F., Remuzzi, G., STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8:November (11) (2012), 622–633, 10.1038/nrneph.2012.195.
144. [144] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT02247479.
145. [145] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT02247531.
146. [146] R. Bansal (2013). Novelmed Therapeutics Anti-properdin antibodies. US Patent 8435512, 5 July 2013. http://www.freepatentsonline.com/8435512.html https://www.google.com/patents/US20140186348.
147. [147] Novelmed Therapeutics. http://www.novelmed.com/ProductPipeline/ParoxysmalNocturnalHemoglobinuria(PNH).aspx.
148. [148] E. Altmann, U. Hommel, E.L.J. Lorthiois, J.K. Maibaum, N. Ostermann, J. Quancard, S.A. Randl, O. Simic, A. Vulpetti, O. Rogel, Ag. Novartis (2012) Indole compounds or analogs thereof as complement factor D inhibitors useful for the treatment of age-related macular degeneration and their preparation. From PCT Int. Appl., WO 2012093101 http://www.google.com/patents/WO2012093101A1?cl=en&hl=it July 12, 2012.
149. [149] M.A. Dechantsreiter, J.E. Grob, A. Mac Sweeney, W. Miltz, S. Randl, R. Sedrani, H. Sellner, F. Sirockin, E. Valeur. Novartis Ag (2013) Preparation of quinazoline compounds as modulators of the complement alternative pathway for treating macular degeneration, diabetic retinopathy, and other diseases. From PCT Int. Appl., WO 2013192345 http://www.google.com.ar/patents/WO2013192345A1?cl=en&hl=it December 27, 2013.
150. [150] S. Flohr, Discovery of highly potent and selective orally bioavailable alternative pathway complement inhibitors? Paper Presented at: 8th International Conference on Complement Therapeutics, Chania, September 1–6, 2015. Aegean Conferences 93, abs 9.
151. [151] Morgan, B.P., Thanassi, J., Podos, S., Phadke, A., Ghadachanda, V., Pais, G., Hashimoto, A., Whang, W., Chen, D., Wang, X., Argawal, A., Deshpande, M., Huang, Y., Wiles, J., Huang, M., Novel small-molecule inhibitors targeting complement factor D for the treatment of paroxysmal nocturnal hemoglobinuria. Blood, 124, 2014, 4817 (published ahead of print December 5, 2014).
152. [152] Wiles, J., Podos, S., Thanassi, J., Phadke, A., Ghadachanda, V., Pais, G., Hashimoto, A., Whang, W., Chen, D., Wang, X., Argawal, A., Rivera, J., Elliott, M., Marlor, C., Zhang, J., Deshpande, M., Huang, M., Huang, Y., Preclinical evaluation of orally bioavailable small-molecule inhibitors of complement factor D as potential treatment for paroxysmal nocturnal hemoglobinuria. Blood, 124, 2014, 4819 (published ahead of print December 5, 2014).
153. [153] Gavriilaki, E., Thanassi, J.A., Yang, G., Yuan, X., Huang, M., Brodsky, R.A., Small Molecule Factor, D., Inhibitors block complement activation in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Blood, 126, 2015, 275.
154. [154] Shi, J., Rose, E.L., Singh, A., Hussain, S., Stagliano, N.E., Parry, G.C., Panicker, S., TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 123:26 (2014), 4015–4022.
155. [155] Jaeger, U., Rose, E.L., Singh, A., Feickert, S.H.A., Panzer, S., Jilma, B., Gilbert, J.C., Panicker, S., Therapeutic rationale and clinical development of TNT009, an upstream classical pathway inhibitor, for cold agglutinin disease. Blood, 126, 2015, 3560.
156. [156] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02502903.
157. [157] Sekine, H., Takahashi, M., Iwaki, D., Fujita, T., The role of MASP-1/3 in complement activation. Adv. Exp. Med. Biol. 735 (2013), 41–53.
158. [158] Takahashi, M.1, Ishida, Y., Iwaki, D., Kanno, K., Suzuki, T., Endo, Y., Homma, Y., Fujita, T., Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J. Exp. Med. 207:January (1) (2010), 29–37, 10.1084/jem.20090633.
159. [159] Oroszlán, G., Kortvely, E., Szakács, D., Kocsis, A., Dammeier, S., Zeck, A., Ueffing, M., Závodszky, P., Pál, G., Gál, P., Dobó, J., MASP-1 and MASP-2 do not activate pro-factor D in resting human blood, whereas MASP-3 is a potential activator: kinetic analysis involving specific MASP-1 and MASP-2 inhibitors. J. Immunol. 196:January (2) (2016), 857–865, 10.4049/jimmunol.1501717.
160. [160] Scwaeble, W.J., The utility of lectin pathway inhibitors as modulators if inflammatory, thrombotic and haemolytic diseases. Paper Presented at: 7th International Conference on Complement Therapeutics, Olympia, June 6–11, 2014, 2014 (Aegean Conferences 82, abs 25).
161. [161] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02222545.
162. [162] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02682407.
163. [163] Kaplan, A.P., Joseph, K., Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv. Immunol. 121 (2014), 41–89, 10.1016/B978-0-12-800100-4.00002-7.
164. [164] Zeerleder, S., Levi, M., Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann. Med. 48:June (4) (2016), 256–267, 10.3109/07853890.2016.1162909.
165. [165] Feussner, A., Kalina, U., Hofmann, P., Machnig, T., Henkel, G., Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema. Transfusion 54:10 (2014), 2566–2573.
166. [166] Lunn, M., Santos, C., Craig, T., Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety. J. Blood Med. 1 (2010), 163–170.
167. [167] DeZern, A.E., Uknis, M., Yuan, X., Mukhina, G.L., Varela, J., Saye, J., Pu, J., Brodsky, R.A., Complement blockade with a C1 esterase inhibitor in paroxysmal nocturnal hemoglobinuria. Exp. Hematol. 42:10 (2014), 857–861.
168. [168] Whaley, K., Ruddy, S., Modulation of the alternative complement pathway by β1H globulin. J. Exp. Med. 144 (1976), 1147–1163.
169. [169] Ricklin, D., Lambris, J.D., Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190:8 (2013), 3831–3838.
170. [170] Holers, V.M., Rohrer, B., Tomlinson, S., CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 735 (2013), 137–154.
171. [171] Fridkis-Hareli, M., Storek, M., Mazsaroff, I., et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118:17 (2011), 4705–4713.
172. [172] Risitano, A.M., Notaro, R., Pascariello, C., et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 119:26 (2012), 6307–6316 (2012).
173. [173] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01335165.
174. [174] Risitano, A.M., Storek, M., Sahelijo, L., Doyle, M., Dai, Y., Weitz, I.C., Marsh, J.C.W., Elebute, M., O'Connell, C.L., Kulasekararaj, A.G., Ramsingh, G., Marotta, S., Hellmann, A., Lundberg, A.S., Safety and pharmacokinetics of the complement inhibitor TT30 in a phase I trial for untreated PNH patients. Blood, 126, 2015, 2137.
175. [175] Schmidt, C.Q., Bai, H., Lin, Z., et al. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J. Immunol. 190:11 (2013), 5712–5721.
176. [176] Hebecker, M., Alba-Domínguez, M., Roumenina, L.T., Reuter, S., Hyvärinen, S., Dragon-Durey, M.A., Jokiranta, T.S., Sánchez-Corral, P., Józsi, M., An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J. Immunol. 191:2 (2013), 912–921.
177. [177] Schmidt, C.Q., Harder, M.J., Nichols, E.M., Hebecker, M., Anliker, M., Höchsmann, B., Simmet, T., ÁI, Csincsi, Uzonyi, B., Pappworth, I.Y., Ricklin, D., Lambris, J.D., Schrezenmeier, H., Józsi, M., Marchbank, K.J., Selectivity of C3-opsonin targeted complement inhibitors: a distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology 221:April (4) (2016), 503–511, 10.1016/j.imbio.2015.12.009.
178. [178] Schmidt, C.Q., Harder, M.J., Nichols, E.M., Hebecker, M., Anliker, M., Höchsmann, B., Simmet, T., ÁI, Csincsi, Uzonyi, B., Pappworth, I.Y., Ricklin, D., Lambris, J.D., Schrezenmeier, H., Józsi, M., Marchbank, K.J., Selectivity of C3-opsonin targeted complement inhibitors: a distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology 221:April (4) (2016), 503–511, 10.1016/j.imbio.2015.12.009.
179. [179] Qiao, Q., Teng, X., Wang, N., Lu, R., Guo, L., Zhang, X., Du, Y., Wang, W., Chen, S., Wu, Q., He, G., Wang, Y., Hu, W., A novel CRIg-targeted complement inhibitor protects cells from complement damage. FASEB J. 28:November (11) (2014), 4986–4999, 10.1096/fj.14-258046 (2014).
180. [180] D. Ricklin, S. Koutsogiannaki, Y. Sarigiannis, N. Papanastasiou, S. Ramesh, S. Hughes, C. Schmidt, K. Ehdahl, B. Nilosoon, J. Lambris, Characterization and optimization of factor-H binding peptide 5C6 as complement-protective coating of artificial surfaces. Paper Presented at: 8th International Conference on Complement Therapeutics, Chania, September 1–6, 2015. Aegean Conferences 93, abs 7.
181. [181] Khera, R., Das, N., Complement receptor 1: disease associations and therapeutic implications. Mol. Immunol. 46:5 (2009), 761–772.
182. [182] Ross, G.D., Lambris, J.D., Cain, J.A., Newman, S.L., Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J. Immunol. 129:5 (1982), 2051–2060.
183. [183] Medof, M.E., Nussenzweig, V., Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J. Exp. Med. 159:6 (1984), 1669–1685.
184. [184] Iida, K., Nussenzweig, V., Complement receptor is an inhibitor of the complement cascade. J. Exp. Med. 153:5 (1981), 1138–1150.
185. [185] Pratt, J.R., Hibbs, M.J., Laver, A.J., Smith, R.A., Sacks, S.H., Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am. J. Pathol. 149:6 (1996), 2055–2066.
186. [186] Zhang, Y., Nester, C.M., Holanda, D.G., Marsh, H.C., Hammond, R.A., Thomas, L.J., Meyer, N.C., Hunsicker, L.G., Sethi, S., Smith, R.J., Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J. Am. Soc. Nephrol. 24:11 (2013), 1820–1829.
187. [187] Smith, R.J.H., Xiao, H., Nester, C.M., Holanda, D.G., Marsh, H.C., Meyer, N.C., Sethi, S., Zhang, Y., Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. Paper Presented at: 7th International Conference on Complement Therapeutics, Olympia, June 6–11, 2014, 2014 (Aegean Conferences 82, abs 37).
188. [188] ClinicalTrials.gov. A service of the U.S. National Institutes of Health. http://clinicaltrials.gov/ct2/show/NCT01791686.
189. [189] Souza, D.G., Esser, D., Bradford, R., Vieira, A.T., Teixeira, M.M., APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br. J. Pharmacol. 145:8 (2005), 1027–1034.
190. [190] Smith, R.A., Membrane-targeted complement inhibitors. Mol. Immunol. 38 (2012), 249–255.
191. [191] Patel, H., Smith, R.A., Sacks, S.H., Zhou, W., Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J. Am. Soc. Nephrol. 17:4 (2006), 1102–1111.
192. [192] Sacks, S., Karegli, J., Farrar, C.A., Asgari, E., Schwaeble, W., Zhou, W., Smith, R.A., Targeting complement at the time of transplantation. Adv. Exp. Med. Biol. 735 (2013), 247–255.
193. [193] International Standard Randomised Controlled Trial Number Register (2104) http://www.controlled-trials.com/ISRCTN49958194.
194. [194] Holers, M., Banda, N., Mehta, G., Fridkis Hareli, M., Or, E., Storek, M., Altman, R., Johnson, K., Katti, S., The human complement receptor 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertase, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity. XXIV International Complement Workshop, Chania, October 10–15, 2012, 2012 (abs #230).
195. [195] Risitano, A.M., Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition. Am. J. Hematol., 6, 2016, 10.1002/ajh.24323.
196. [196] Reis, E.S., Falcao, D.A., Isaac, L., Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand. J. Immunol. 63:3 (2006), 155–168.
197. [197] Botto, M., Kirschfink, M., Macor, P., Pickering, M.C., Würzner, R., Tedesco, F., Complement in human diseases: lessons from complement deficiencies. Mol. Immunol. 46:14 (2009), 2774–2783.
198. [198] Höchsmann, B., Dohna-Schwake, C., Kyrieleis, H.A., Pannicke, U., Schrezenmeier, H., Targeted therapy with eculizumab for inherited CD59 deficiency. N. Engl. J. Med. 370:January (1) (2014), 90–92, 10.1056/NEJMc1308104.
199. [199] Höchsmann, B., Schrezenmeier, H., Congenital CD59 deficiency. Hematol. Oncol. Clin. North Am. 29:June (3) (2015), 495–507, 10.1016/j.hoc.2015.01.006.
200. [200] Nevo, Y., Ben-Zeev, B., Tabib, A., et al. CD59 deficiency is associated with chronic hemolysis and childhood relapsing immunemediated polyneuropathy. Blood 121 (2013), 129–135.
201. [202] Morgan, B.P., Harris, C.L., Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14:December (12) (2015), 857–877, 10.1038/nrd4657.